Working with Industry Partners

The Center for Bioelectrics' primary mission is to carry out scientific research that increases our understanding of the interaction of electromagnetic fields and ionized gases with biological systems, and to use this knowledge to optimize and develop applications in biotechnology, medical diagnostics and therapeutics. From time to time, research interests of Center faculty converge with an industrial entity seeking answers to similar scientific questions, and the opportunity for industry to sponsor research at the Center arises. The Center supports and welcomes industry-sponsored projects that promote scientific advancements and stimulate the effective use of new knowledge.

Pulse Biosciences

Pulse Biosciences is a bioelectric medicine company focused on technology and products utilizing nanosecond electric pulses to treat a range of dermatologic conditions and tumors. The technology originated at the Frank Reidy Research Center for Bioelectrics at Old Dominion University and in the labs of Professor Martin Gundersen in the Department of Electrical Engineering at the University of Southern California. The spinout of this bioelectrics technology to Pulse Biosciences was a first for Old Dominion University and an example of a university-developed technology reaching the marketplace. Bioelectrics' pathbreaking work has been recognized as the most successful university-based initial public offering (IPO) in the stock market-ever and the largest single commercialization effort achieved at Old Dominion University. The Pulse Bioesciences' IPO resulted in a revenue of approximately $41 million to Old Dominion University and its inventors.

The CellFX® System is the first commercially available product to harness the distinctive advantages of Nano-Pulse Stimulation (NPS™) technology. Initial target applications are a range of dermatologic conditions that share high demand among patients and practitioners for improved outcomes. The CellFX® System has received FDA, CE mark and Health Canada approvals.

 

Generators

From left to right: Engineering prototype developed at the Center, two models developed in the Pulse Biosciences' engineering lab and the final commercial CellFX® system

Sponsored Research

PRINCIPAL INVESTIGATOR TITLE YEAR
CLAUDIA MURATORI NANO-PULSE STIMULATION FOR TREATMENT OF DIABETIC SKIN & SOFT TISSUE MRSA INFECTI 2021
ANDREI PAKHOMOV MECHANISMS UNDERLYING THE SENSITIVITY OF SMOOTH MUSCLE CELLS TO NPS 2021
ANDREI PAKHOMOV MINIMIZING NEUROMUSCULAR EXCITATION FROM NPS ABLATION 2019
CLAUDIA MURATORI ACTIVATION OF THE DENDRITIC CELL-T AXIS BY nsPEF TREATMENTS 2019
P. THOMAS VERNIER INFLAMMASOME ACTIVATION, CYTOKINE RELEASE, AND CYTOTOXICITY IN RESPONSE TO nsPEF 2019
STEPHEN BEEBE NANOPULSE STIMULATION & IMMUNE MODULATORS TO ENHANCE ANTI- TUMOR IMMUNE RESPONSE 2018
ANDREI PAKHOMOV PERIPHERAL NERVE STIMULATION WITH UNI-AND BIPOLAR NANOSECOND PULSES 2018
CLAUDIA MURATORI NANOSECOND PULSE STIMULATION TO BOOST THE IMMUNOGENICITY OF TUMOR CELL DEATH 2018
SHU XIAO NANOSECOND PULSING TOWARDS EXTREME FREQUENCY 2018
CLAUDIA MURATORI INVESTIGATING CUTIBACTERIUM ACNES INACTIVATION BY NANOSECOND PULSE STIMULATION 2018
P. THOMAS VERNIER HYDROXYL RADICAL GENERATION AND DENDRITIC CELL ACTIVATION 2017
CLAUDIA MURATORI EXPLORING MULTIMODAL CANCER CELL DEATH INDUCED BY NPS IN VIVO 2017
SHU XIAO TARGET ADIPOSE TISSUE IN THE TREATMENT OF OBESITY USING PPA 2017
CHRISTIAN ZEMLIN COMPARING THE EFFICACIES OF NANOSECOND PULSED ELECTRIC FIELD ABLATION AND RF AB 2017
SIQI GUO NSEPS AS AN ABLATION-INMMUNOTHERAPY FOR ADVANCED PANCREATIC CANCER 2016
STEPHEN BEEBE MECHANISMS THAT INDUCE IMMUNOGENIC CELL DEATH 2016
CHRISTIAN ZEMLIN ABLATING CARDIC TISSUE WITH NANOSECOND PULSE 2016
JOHN CATRAVAS SYNERGISTIC ACTIONS OF NSPEF HSP90 INHIBITORS 2016
RICHARD HELLER ELECTROBLATE TASK ORDER 1 2015
OLGA PAKHOMOVA ELECTROBLATE TASK ORDER 2 2015
STEPHEN BEEBE ELECTROBLATE TASK ORDER 3 2015
ANDREI PAKHOMOV ELECTROBLATE TASK ORDER 4 2015